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Abstract
Background: Despite the availability of antiretroviral therapy (ART), suboptimal treatment outcomes have been
observed among HIV-seropositive illicit drug users. As there is an urgent need to improve responses to
antiretroviral therapy among this population, we undertook this study to evaluate the role of physician experience
on rates of plasma HIV-1 RNA suppression following initiation of ART.
Methods: Using data from a community-recruited cohort of HIV-positive illicit drug users, we used Cox
proportional hazards regression to model the time to plasma viral HIV RNA < 500 copies/mL among antiretroviral-
naïve subjects initiating ART. Physician experience was defined as a continuous variable measured per 100 HIV-
infected patients previously enrolled in the province-wide HIV treatment registry by that physician at the time a
patient was enrolled.
Results: Between May 1996 and December 2008, 267 individuals initiated ART among whom 227 (85%) achieved a
plasma HIV RNA < 500 copies/mL during the study period. In a multivariate analysis, greater physician experience
was independently associated with higher rates of plasma HIV RNA suppression (adjusted hazard ratio [AHR] = 1.17,
95% confidence interval [CI]: 1.03-1.34) after adjustment for adherence to ART. Other factors associated with viral
suppression included engagement in methadone maintenance therapy (AHR = 1.61, 95% CI: 1.23-2.09), ≥ 95%
adherence to ART (AHR = 2.42, 95% CI: 1.80-3.26), baseline CD4 count (AHR = 0.89, 95% CI: 0.83-0.96) and baseline
plasma HIV-1 RNA (AHR = 0.65, 95% CI: 0.53-0.81).
Conclusions: In this setting of universal HIV/AIDS care, illicit drug users with more experienced physicians
exhibited faster rates of plasma viral load suppression. These findings argue for specialized services to help
optimize HIV treatment outcomes among this population.
Background
With over 30 million cases distributed worldwide, the
HIV/AIDS pandemic is a global public health emergency
[1]. In areas outside sub-Saharan Africa, nearly one in
three new infections occur among individuals who use
illicit drugs [2]. Current treatment guidelines recom-
mend the initiation of antiretroviral therapy in order to
durably suppress HIV-1 plasma HIV RNA levels in
order to reduce morbidity, mortality and the risk of HIV
transmission [3].
Despite the availability of effective treatment, several
individual, social and structural factors have posed bar-
riers to effective ART outcomes among illicit drug
users. While access and adherence to the prescribed
drug regimen is recognized as the most important deter-
minant of treatment success [4], other factors, including
clinical status at treatment initiation, specific illicit drug
use patterns [5] and homelessness [6], may also play a
role. Less well evaluated is the role of healthcare factors,
such as the role of prescribing physicians. Previous stu-
dies have indicated that physicians may be less willing
to prescribe ART to illicit drug users [7]. However, the
effect of provider characteristics on outcomes from ART
has not been previously examined among drug-using
HIV-infected populations. Therefore, we examined the
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influence of physician experience on achieving plasma
viral HIV-1 RNA < 500 copies/mL among injection
drug users initiating ART.
Methods
Data for this study were obtained from the AIDS Care
Cohort to evaluate Exposure to Survival Services
(ACCESS), an ongoing observational prospective cohort
of HIV-positive illicit drug users [8,9]. Following recruit-
ment through street outreach and the provision of
informed consent, participants provide a blood sample
and complete an extensive interviewer-administered
questionnaire as well as a nurse-administered examina-
tion. Follow-ups occur semi-annually. Most of these
individuals reside in the Downtown Eastside (DTES)
neighbourhood, an area in Vancouver, Canada, with
high prevalence of illicit drug use, poverty and home-
lessness, as well as HIV and hepatitis C infection [8,9].
Individuals from the ACCESS cohort were aged 18 years
or older at recruitment, tested seropositive to HIV-1
and had used non-cannabinoid illicit drugs in the
month prior to enrolment. ACCESS has been approved
by the University of British Columbia/Providence
Healthcare Research Ethics Board.
Data on HIV clinical monitoring and drug-using beha-
viour were augmented with information on HIV care
and treatment outcomes from the province-wide centra-
lized ART dispensary and HIV clinical monitoring
laboratory at the British Columbia Centre for Excellence
in HIV/AIDS (BC-CfE) [8,9]. As a result, we had access
to a complete profile of CD4 cell count and plasma
HIV-1 RNA level for each participant. ART adherence
was defined as the number of days ART was dispensed
over the number of days an individual was eligible for
ART in the previous 6 months; the resulting proportion
was dichotomized as > 95% vs. ≤ 95% adherence. Pre-
vious studies have validated this method of measuring
ART adherence using pharmacy refill data [10]. Mea-
surements of plasma HIV-1 RNA were obtained using
the Roche Amplicor Monitor assay (Roche Molecular
Systems, Mississauga, Canada.)
This study included all ACCESS participants who
were ART-naïve at recruitment, initiated treatment dur-
ing the study period, and had at least one clinical test
measuring CD4 cell count and plasma HIV-1 RNA level
during the first 12 months on ART. Our main outcome,
time to plasma HIV-1 RNA suppression, was operatio-
nalized as the date of the first observation with a plasma
viral HIV-1 RNA < 500 copies/mL.
The primary explanatory variable of interest was phy-
sician experience, defined as the number of patients that
the participant’s prescribing physician had previously
enrolled in the province-wide HIV treatment registry.
This was considered as a continuous variable and, since
physicians could become more experienced over time,
was fixed for each participant at the time they initiated
ART. In British Columbia, antiretroviral prescribing
physicians could be located anywhere in the province
and not at only one institution. Patients selected antire-
troviral-prescribing primary care or specialist physicians
in a non-random manner through self-selection or refer-
ral from other physicians. Physician experience was
fixed as a baseline characteristic at the time the patient
initiated ART as we believe that this was the best way
to estimate physician experience. We recognized certain
behaviours (e.g. drug use activity) could confound this
association so these measures were treated as time-
updated variables based on each participant’s semi-
annual follow up visit.
Several variables that could influence the association
between physician experience and plasma HIV-1 RNA
suppression were also assessed, including age, gender
(female vs. male), Aboriginal ancestry (yes vs. no) and
Downtown Eastside residence (yes vs. no). Clinical vari-
ables included ART adherence (≥ 95% vs. < 95% in first
year of treatment), current enrolment in methadone
maintenance therapy (no vs. yes), protease inhibitor as
part of the first ART regimen (yes vs. no), CD4 cell
count at baseline (per 100 cells), plasma HIV-1 RNA
level at baseline (per log10 increase) and the year of
ART initiation (per more recent year). Illicit drug use
measures included daily cocaine use (yes vs. no) and
daily heroin use (yes vs. no) and referred to the six-
month period prior to the interview. Patients were pre-
scribed antiretroviral therapy consistent with therapeutic
guidelines which, beginning in 1996 for all patients,
recommended triple combination therapy. While the
drugs used over the study period changed markedly
over time, consistent with previous analyses, we adjusted
for whether protease inhibitors were used in the initial
regimen or not as a strategy to adjust for confounding
that could occur as a result of regimen type. Given the
large number of nucleosides used in the backbone of
the ART regimen during the study period, we elected to
not adjust for this in the analysis.
We initially examined baseline characteristics of our
cohort, including physician experience, and tested for
significant differences using Pearson’s c2 statistic. We
subsequently used univariate and multivariate Cox pro-
portional hazards regression to evaluate the impact of
the variables considered on the time to plasma HIV-1
RNA < 500 copies/mL. The multivariate model was
built using an a priori model building strategy developed
by Greenland and colleagues [11]. This strategy aims to
produce a parsimonious set of covariates to better esti-
mate the adjusted relationship between a primary expla-
natory variable and an outcome of interest. It has
previously been used, for example, to assess the
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independent relationship between incarceration patterns
and non-adherence to ART among injection drug users
[12]. To start, we fitted a multivariate model that
included physician experience and the full set of second-
ary explanatory variables. After noting the value of the
regression coefficient associated with physician experi-
ence in the full model, we used a manual stepwise
approach to fit a series of reduced models, each with
one secondary explanatory variable dropped from the
full set. Comparing the value of the coefficient in the
full model to the value of the coefficient for physician
experience in each of the reduced models, we dropped
the variable associated with the smallest relative change
from further consideration. This iterative process was
continued until the maximum change exceeded 5%.
This technique has been employed in several studies to
estimate the independent effect of an explanatory vari-
able on an outcome of interest [12].
Results
Between May 1996 and December 2008, 267 ART-naïve
IDU who initiated ART over follow-up were recruited.
This group included 124 (46.4%) women and 105
(39.3%) individuals who reported being of Aboriginal
ancestry. The baseline characteristics of the study sam-
ple along with the median physician experience of dif-
ferent groups are presented in Table 1. As shown here,
individuals engaged in methadone maintenance therapy
had the most experienced providers (median = 60, inter-
quartile range [IQR]: 20-144), while individuals residing
outside of the Downtown Eastside were treated by pro-
viders with the least experience (median = 28, IQR: 8-92).
During the study period, 227 participants (85.0%)
achieved at least one observation of plasma HIV-1 RNA
< 500 copies/mL, reflecting an incidence density of 65.2
per 100 person years (95% CI: 57.0-74.2). Table 2 pre-
sents the unadjusted hazard ratios (HR) of time to
plasma HIV-1 RNA suppression by physician experience
as well as other explanatory covariates. As shown, physi-
cian experience (per 100 patients previously enrolled)
was significantly associated with time to suppression
(HR = 1.25, 95% CI: 1.10-1.42, p-value < 0.001), as were
older patient age (HR = 1.26 per 10 years, 95% CI: 1.08-
1.47, p-value = 0.004), engagement in methadone main-
tenance therapy (HR = 1.54, 95% CI: 1.18-2.00, p-value
= 0.001), ≥ 95% ART adherence (HR = 4.12, 95% CI:
3.10-5.54, p-value < 0.001), CD4 cell count (HR = 0.90,
95% CI: 0.84-0.96, p-value = 0.003), baseline plasma
viral load (HR = 0.71, 95% CI: 0.58-0.87, p-value =
0.001), and the year of ART initiation (HR = 1.17 per
more recent year, 95% CI: 1.12-1.21, p-value < 0.001.)
Table 2 presents adjusted hazard ratios (AHR) of time
to plasma HIV-1 RNA suppression by physician experi-
ence as well as other covariates. As shown here,
physician experience was independently associated with
plasma HIV-1 RNA suppression (AHR = 1.17, 95% CI:
1.03-1.34, p-value = 0.031). Other factors that were
associated with time to plasma HIV-1 RNA suppression
in this multivariate analysis included methadone mainte-
nance therapy (AHR = 1.61, 95% CI: 1.23-2.09, p-value
< 0.001), baseline CD4 count (AHR = 0.89, 95% CI:
0.83-0.96, p-value < 0.001), baseline log10 HIV-1 RNA
(AHR = 0.65, 95% CI: 0.53-0.81, p-value < 0.001) and
adherence to ART (AHR = 2.42, 95% CI: 1.80-3.26,
p-value < 0.001). When we fit a multivariate model
including the three main associations shown in Table 1,
we found that physician experience was associated with
higher rates of plasma HIV-1 RNA viral load suppres-
sion (AHR = 1.23 per 100 patients enrolled, 95% CI:
1.07-1.40, p-value = 0.003) after adjustment for Down-
town Eastside residence, methadone maintenance ther-
apy and daily cocaine injection.
Table 1 Baseline characteristics of 267 HIV-seropositive
active illicit drug users including physician experience
Characteristic All (267) Physician experience p-value
n (%) Median (IQR3)
Gender
Male 143 (53.6) 41 (13-98) 0.434
Female 124 (46.4) 48 (13-130)
Aboriginal ancestry
No 162 (60.7) 55 (15-103) 0.716
Yes 105 (39.3) 42 (10-116)
DTES residence
No 83 (31.1) 28 (8-92) 0.018
Yes 184 (68.9) 56 (16-123)
ART adherence
≤ 95% in first year 186 (69.7) 42 (10-103) 0.078
> 95% in first year 81 (30.3) 58 (22-127)
Methadone maintenance
No 160 (59.9) 38 (11-90) 0.003
Yes 107 (40.1) 60 (20-144)
Daily cocaine use1
No 175 (65.5) 59 (13-126) 0.045
Yes 92 (34.5) 34 (12-92)
Daily heroin use1
No 196 (73.4) 47 (13-104) 0.658
Yes 71 (26.6) 43 (14-116)
PI2 in first ART regimen
No 155 (58.1) 44 (14-105) 0.975
Yes 112 (41.9) 58 (12-111)
1. Refers to the six-month period prior to baseline
2. Protease inhibitor
3. Inter-quartile range. Physician experience was defined as per 100 HIV-
infected patients previously treated by that physician at the time each
participant initiated ART.
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In a sub-analysis, we explored the impact of physician
experience on time to viral load suppression when phy-
sician experience was defined as a categorical variable
using tertiles. In the first tertile, physicians had treated
less than 22 patients previously and the median time to
plasma HIV-1 RNA < 500 copies/mL was 9.5 months
(95% CI: 4.4-14.5). In the middle tertile, physicians had
treated 22-81 patients previously and the median time
to suppression was 6.2 months (95% CI: 3.0-13.4). In
the most experienced tertile, physicians had treated
greater than 81 patients previously and the median time
to plasma HIV RNA suppression < 500 copies/mL was
3.0 months (95% CI: 2.3-4.7).
Discussion
In this study, we found that greater physician experience
was positively associated with the time to viral load
suppression among drug users initiating ART. This
association persisted in a multivariate model after
adjusting for CD4 cell count, baseline plasma HIV-1
RNA level, methadone use, and adherence following
ART initiation.
Our finding that physician experience was associated
with higher rates of plasma HIV-1 RNA suppression is
noteworthy. Prior to the advent of combination antire-
troviral therapy, a US study found that higher physician
experience was associated with longer patient survival
[13]. Similar results have also been reported in the era
of combination antiretroviral therapy [14]. Previous stu-
dies have also shown that negative attitudes among phy-
sicians towards HIV-positive drug users are linked to
lower quality of care [7]. At the same time, the more
drug users a physician has seen, the more likely he or
she is to report a positive attitude toward injection drug
users [7]. Previous studies also suggest that physicians
often base their judgment regarding patient’s level of
Table 2 Univariate and multivariate analyses of factors associated with time to HIV-1 RNA < 500 copies/mL among
individuals beginning antiretroviral therapy
Characteristic Hazard Ratio 95% CI3 p-value Adjusted Hazard Ratio 95% CI3 p-value
Physician experience1
Per 100 patients 1.25 1.10-1.42 < 0.001 1.17 1.04-1.34 0.031
Age1
Per 10 years 1.26 1.08-1.47 0.004
Gender1
Female vs. male 0.95 0.73-1.24 0.711
Aboriginal ancestry1
Yes vs. no 1.05 0.80-1.36 0.103
DTES residence2
Yes vs. no 1.13 0.86-1.49 0.788
Methadone maintenance2
Yes vs. no 1.54 1.18-2.00 0.001 1.61 1.23-2.09 < 0.001
Daily cocaine use2
Yes vs. no 0.92 0.68-1.24 0.578
Daily heroin use2
Yes vs. no 0.78 0.57-1.08 0.137
ART adherence2
> 95% vs. ≤ 95% 4.12 3.10-5.54 < 0.001 2.42 1.80-3.26 < 0.001
PI in first regimen1
Yes vs. no 1.23 0.95-1.61 0.117
CD4 cell count1
Per 100 cells 0.90 0.84-0.96 0.003 0.89 0.83-0.96 0.001
Plasma viral load1
Per log10 increase 0.71 0.58-0.87 0.001 0.65 0.53-0.81 < 0.001
Year of ART initiation1
Per more recent year 1.17 1.12-1.21 < 0.001
1. Time invariant, observed at baseline
2. Time varying, observed every 6 months
3. 95% Confidence Interval
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adherence on non-medical clues such as socio-demo-
graphic criteria [15]. At the same time, attempts of clini-
cians to predict patient adherence to ART pre-initiation
are often incorrect [16]. Less experienced physicians
may carry a preconceived belief that drug users tend to
be non-adherent. Such usage of extra-medical cues,
even if shown to be indicative at times [17], could
potentially lead to a patient’s mistrust in the health care
provider and facilitate a decline in the quality of doctor-
patient communication [18].
Although our measure of adherence has been pre-
viously validated to predict plasma HIV RNA responses
[10], CD4 count responses [19] and patient survival [9],
it is possible that residual confounding related to
patient adherence–and possibly mediated by physician
experience–explain our findings. Specifically, it is pos-
sible that having an experienced physician contributed
to positive daily adherence behaviour that was not cap-
tured by pharmacy refill. In addition, while this study
demonstrated an association between physician experi-
ence and higher rates of plasma HIV RNA suppression,
we were not able to explore explanations for this asso-
ciation. It is likely that physicians with greater HIV-
related experience were able to more skilfully address
drug toxicities and other concerns that may limit
patient adherence.
Our study has some limitations to be noted. First,
our cohort was not randomly selected and therefore
may not be representative of all HIV-infected drug
users in Vancouver or elsewhere. Second, although
physician experience was defined based on an HIV
treatment registry, for other variables we relied on
measures of self-report, and therefore response bias
could have undermined our ascertainment of sensitive
behaviours, including illicit drug use and addiction
treatment use. Finally, our analyses only includes fol-
low-up information until 2008 and data collected when
the lower limit of detection was 500 copies/mL. Future
studies should continue to assess whether physician
experience is associated with outcomes from HIV
treatment, especially as modern HAART regimens are
increasingly simple to take.
Conclusions
In summary, we examined plasma HIV RNA responses
after the initiation of ART among a long-running com-
munity-recruited prospective cohort of HIV-positive illi-
cit drug users and observed that lower HIV-related
experience of physicians was independently associated
with lower rates of plasma HIV RNA suppression.
These findings argue for more specialized treatment
approaches to address the HIV treatment needs of this
challenging population.
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